COVID-19 vaccines and cancer care: the known, the unknown and the unknowable: ESMO Live Roundtable
A panel of renowned experts in oncology, immunology and virology discuss the main issues on the use of COVID-19 vaccines in cancer patients
Related Articles
Antonio Passaro on LinkedIn: #esmo #sboc
🌎 I am deeply honored to have been a part of the ESMO SUMMIT LATIN AMERICA in Sao Paolo del Brasile 🇧🇷 this past Saturday,…
Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations
BAY 2927088 is an oral, small molecule tyrosine kinase inhibitor under development as a potential new targeted therapy for patients with NSCLC harboring HER2 activating…
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients – PubMed
Epidermal growth factor receptor (EGFR) exon 20 insertions occur rarely among different cancer types, with the highest frequency reported among non-small-cell lung cancer (NSCLC) patients,…
Amivantamab-Based Regimens Show Anticancer Activity in EGFR-Mutated Advanced NSCLC – The ASCO Post
Widely anticipated findings from the MARIPOSA1 and MARIPOSA-22 trials were presented at the European Society for Medical Oncology (ESMO) Congress 2023, showing potentially improved outcomes…
Takeda Provides Update on Lung Cancer Program
Takeda will be working with the FDA towards a voluntary withdrawal of EXKIVITY (mobocertinib) in the U.S. and globally where it is currently available.
Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy With and Without Lazertinib versus Chemotherapy Alone in Patients with EGFR-Mutated Non-S
/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the three-arm Phase 3 MARIPOSA-2 study…
Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use…
Treatment with RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with Newly Diagnosed EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the Phase 3 PAPILLON study evaluating…
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre…
Recommendation based on results from the Phase 3 CheckMate -816 trial, in which Opdivo with chemotherapy demonstrated improved event-free survival and pathologic complete response compared…
Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial
Results support potential for a new treatment option that builds on the benefit of first-line standard of care Tagrisso monotherapy Positive high-level results from…